Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed that HKY could induce apoptosis in colon cancer cell line through downregulation of p-Akt1, Rel A, Bcl-XL, pro-caspase 3, and pro-caspase 9 expressions, and upregulation of BAX, cleaved caspase-3, and cleaved caspase-9.
|
30788662 |
2020 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the molecular mechanisms of targeting AKT by SC66 during colon cancer therapy are not well understood.
|
31168297 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> JSD reverses EMT and inhibits invasion and metastasis of colon cancer through the AKT/GSK-3β signaling pathway.
|
31772677 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results revealed that resveratrol treatment and AKT1 knockdown significantly inhibited cell migration and invasion in colon cancer, and markedly increased E‑cadherin expression and decreased that of N‑cadherin, phospho (p)‑AKT1, p‑GSK‑3β, and Snail in colon cancer both in vitro and in vivo.
|
31524255 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, the present results suggest that the targeting effects of resveratrol to AKT1 and AKT2 may be a potent strategy for chemoprevention or therapy for colon cancer.
|
30387805 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemokine receptor 7 targets the vascular endothelial growth factor via the AKT/ERK pathway to regulate angiogenesis in colon cancer.
|
31348616 |
2019 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression or silencing of TUSC3 could partially reverse the effects of the overexpression or repression of miR-873-5p on colon cancer progression caused by activation of the AKT pathway.
|
31039290 |
2019 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AKT overexpression could partly reverse the attenuated colon cancer cell growth caused by miR-302a-3p mimic transfection.
|
31502038 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRR14 overexpression promotes cell growth, epithelial to mesenchymal transition and metastasis of colon cancer via the AKT pathway.
|
31596887 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selectively blocking FAK-Akt1 interaction by a peptide derived from the FAK-Four-point-one, ezrin, radixin, moesin (FERM) domain reduces colon cancer cell adhesion <i>in vitro</i> and in mice.
|
31186741 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCRP-1 regulates EGFR-AKT-BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer.
|
30518879 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to explore whether LINC00657 can regulate cell proliferation and invasion by regulating the PI3K/AKT pathway and thus participate in the occurrence of colon cancer.
|
30338799 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggested that tunicamycin may inhibit growth and aggressiveness of colon cancer via the ERK‑JNK‑mediated AKT/mTOR signaling pathway, and suggested that tunicamycin may be a potential anti‑cancer agent for colon carcinoma therapy.
|
29344654 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of the present study verified that the protective effects of miRNA-29a suppress the PTEN/Akt/GSK3β and Wnt/β-catenin signaling pathways in colon cancer.
|
30013659 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The FPRL2 played a significant role in colon cancer drug resistance and this effect was through AKT pathway.
|
29364475 |
2018 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings demonstrate a heretofore unappreciated, but critical, role for nCDase in enabling/maintaining basal activation of AKT and also suggest that nCDase is a suitable novel target for colon cancer therapy.
|
29662189 |
2018 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anti-colon cancer activity of Murraya koenigii leaves is due to constituent murrayazoline and O-methylmurrayamine A induced mTOR/AKT downregulation and mitochondrial apoptosis.
|
28675857 |
2017 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that upregulation of miR-542-3p inhibited the growth and invasion of colon cancer cells through PI3K/AKT/survivin signaling, highlighting a novel therapeutic approach for the treatment of colon cancer.
|
29130099 |
2017 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
INPP4B inhibits PtdIns(3,4)<i>P</i><sub>2</sub>-mediated AKT activation in breast and prostate cancer; however, INPP4B expression is increased in acute myeloid leukaemia (AML), melanoma and colon cancer where it paradoxically promotes cell proliferation, transformation and/or drug resistance.
|
28082369 |
2017 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Axis of CXCR4/SDF-1 Plays a Role in Colon Cancer Cell Adhesion Through Regulation of the AKT and IGF1R Signalling Pathways.
|
28739729 |
2017 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, DLD-1 isogenic AKT1, AKT2 and AKT1/2 knockout colon cancer cell lines were used as a model system in conjunction with the parental cell line in order to further elucidate the differences between the AKT isoforms and how they are involved in various cellular pathways.
|
27878243 |
2017 |
Malignant tumor of colon
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the in vitro study was to investigate the anticancer activity of InsP6 on colon cancer with the focus on inhibiting the AKT1 kinase and p70S6K1 as mTOR effector, in relation to proliferation and apoptosis of cells.
|
28972559 |
2017 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pre-treatment with curcumin followed by 5-Fu may mediate autophagy turnover both in vitro and in vivo via AMPK/ULK1-dependent autophagy inhibition and AKT modulation, which may account for the increased susceptibility of the colon cancer cells/xenograft to the cytotoxicity of 5-Fu.
|
29273065 |
2017 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The abnormal MSI (21.7%) and KRAS (44.6%), BRAF (8.6%), PIK3CA (19.4%), AKT1 (2.2%), and TGF - βR (9.6%) mutation frequencies were significantly higher in proximal colon cancer.
|
26471487 |
2016 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
microRNA-374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway.
|
27191497 |
2016 |